Abstract
Retinal vein occlusions are still one of the leading retinal vasculopathies with a strong impact on the quality of life. Despite the success in symptomatic treatment with anti-vascular endothelial growth factor (VEGF) medication, no real causal therapy has been developed so far. As most of the pathogenetic changes have been observed in the vitreoretinal interface, actual therapeutic strategies are being focused on this area. Modern surgical techniques may help to release vitreovascular traction, stop cytokine activation and improve retinal oxygenation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
